TickerFacts.

Myriad Genetics Inc (MYGN): Net Income

Annual figures by period end, from SEC filings.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2017-06-30 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

-$365.90M
Year ended 2025-12-31
-$112.60M
Trailing 12 months to 2026-06-30
$176.20M2009-06-30: $84.61M2010-06-30: $152.30M2011-06-30: $100.71M2012-06-30: $112.15M2013-06-30: $147.20M2014-06-30: $176.20M2015-06-30: $79.80M2016-06-30: $117.20M2017-06-30: $17.40M2018-06-30: $133.30M2019-06-30: $4.60M2020-12-31: -$223.60M2021-12-31: -$27.20M2022-12-31: -$112.00M2023-12-31: -$263.30M2024-12-31: -$127.30M2025-12-31: -$365.90M-$365.90M
2009-06-30 Net Income (USD) 2025-12-31
Period endedNet IncomeChange YoYSource filing
2025-12-31-$365.90Mn/m2026-02-24, From 2025-01-01
2024-12-31-$127.30Mn/m2026-02-24, From 2024-01-01
2023-12-31-$263.30Mn/m2026-02-24, From 2023-01-01
2022-12-31-$112.00Mn/m2025-02-28, From 2022-01-01
2021-12-31-$27.20Mn/m2024-02-28, From 2021-01-01
2020-12-31-$223.60Mn/a2022-02-25, From 2020-01-01
No annual figure between 2019-06-30 and 2020-12-31.
2019-06-30$4.60M-96.5%2022-02-25, From 2018-07-01
2018-06-30$133.30M+666.1%2020-08-13, From 2017-07-01
2017-06-30$17.40Mn/c2019-08-13, From 2016-07-01
2016-06-30$117.20M+46.9%2018-08-24, From 2015-07-01
2015-06-30$79.80M-54.7%2018-08-24, From 2014-07-01
2014-06-30$176.20M+19.7%2016-08-10, From 2013-07-01
2013-06-30$147.20M+31.3%2015-08-12, From 2012-07-01
2012-06-30$112.15M+11.4%2014-08-13, From 2011-07-01
2011-06-30$100.71M-33.9%2013-08-14, From 2010-07-01
2010-06-30$152.30M+80.0%2012-08-15, From 2009-07-01
2009-06-30$84.61Mn/a2011-08-15, From 2008-07-01

Net Income at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedNet IncomeChange YoY
Myriad Genetics Inc (MYGN)2025-12-31-$365.90Mn/m
Neogen Corp (NEOG)2026-05-31-$7.90Mn/m
Lantheus Holdings, Inc. (LNTH)2025-12-31$233.56M-25.2%
QuidelOrtho Corp (QDEL)2025-12-28-$1.13Bn/m
Idexx Laboratories Inc (IDXX)2025-12-31$1.06B+19.3%
Intellia Therapeutics, Inc. (NTLA)2025-12-31-$412.69Mn/m
Alpha Teknova, Inc. (TKNO)2025-12-31-$17.26Mn/m
Immucell Corp (ICCC)2025-12-31-$1.04Mn/m
Aspira Women's Health Inc. (AWHL)2025-12-31-$12.78Mn/m

Compare MYGN, NEOG, LNTH, QDEL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗